文献速递病毒性肝炎

脂肪肝与慢性乙型肝炎患者肝硬化、肝细胞癌及HBsAg清除的关联

Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B.
PubMed 文献 · J Infect Dis · 2021-01-01

本研究为6786例成人慢性乙型肝炎患者的回顾性队列研究,采用倾向性评分匹配平衡脂肪肝合并非脂肪肝组。脂肪肝与更低的肝硬化、肝细胞癌风险及更高的HBsAg清除率相关,抗病毒治疗患者中脂肪肝与肝硬化风险降低显著相关(HR 0.19)。

要点

  • 脂肪肝合并慢性乙肝患者10年肝硬化、肝癌累积率更低,HBsAg清除率更高。
  • 抗病毒治疗患者中脂肪肝与肝硬化风险降低独立相关(HR 0.19)。
  • 未治疗患者中脂肪肝与肝硬化、肝癌风险无显著关联。

核心结论

  • 脂肪肝与慢性乙型肝炎患者更低的肝硬化和肝细胞癌风险及更高的HBsAg清除率显著相关。
  • 脂肪肝对肝硬化、肝癌风险的保护性关联仅在抗病毒治疗患者中显著。

研究设计与样本

  • 回顾性队列研究,纳入6786例成人慢性乙型肝炎患者。
  • 采用倾向性评分匹配平衡脂肪肝合并非脂肪肝组,并用Kaplan-Meier法比较累积率。

主要发现

  • 匹配前脂肪肝合并非脂肪肝患者10年肝硬化、肝癌累积率更低,HBsAg清除率更高。
  • 匹配后及抗病毒治疗匹配队列中结果相似。
  • 未治疗患者中脂肪肝与肝硬化、肝癌风险无显著关联。

临床怎么用

  • 慢性乙型肝炎患者合并脂肪肝时,不应仅因脂肪肝而低估其肝硬化、肝癌风险,需结合抗病毒治疗状态综合评估。
  • 抗病毒治疗患者中脂肪肝与更好的肝脏结局相关,但仍需进一步研究确认机制。

局限性

  • 回顾性研究设计可能存在残余混杂。
  • 作者指出需进一步研究确认其发现并探究脂肪肝影响慢性乙型肝炎的机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic hepatitis B (CHB) and fatty liver (FL) are common, natural history data on concurrent FL and CHB (FL-CHB) are limited. This study aimed to evaluate the effect of FL on cirrhosis, hepatocellular carcinoma (HCC), and hepatitis B surface antigen (HBsAg) seroclearance incidence in CHB patients. METHODS: In a retrospective cohort study of 6786 adult CHB patients, we used propensity score matching (PSM) to balance the FL-CHB and non-FL CHB groups. Kaplan-Meier methods were used to compare cumulative cirrhosis, HCC, and HBsAg seroclearance rates between subgroups. RESULTS: Before PSM, compared to non-FL CHB, FL-CHB patients had lower 10-year cumulative rates of cirrhosis, HCC, and a higher HBsAg seroclearance rate. Similar results were found in the matched FL-CHB and non-FL CHB patients, as well as in the antiviral-treated PSM cohort. Cox proportional hazards model indicated FL to remain significantly and strongly associated with lower risk of cirrhosis and HCC (hazard ratio [HR], 0.19 [95% confidence interval {CI}, .12-.33], P < .001 and HR, 0.21 [95% CI, .09-.51], P = .001, respectively) in antiviral-treated patients but not in untreated patients. CONCLUSIONS: FL was significantly associated with lower cirrhosis and HCC risk and higher HBsAg seroclearance. Further studies are needed to confirm our funding and investigate the mechanisms underlying the impact of FL on CHB.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Li J, Yang HI, Yeh ML, et al. Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. J Infect Dis. 2021. PMID: 33249474. doi:10.1093/infdis/jiaa739

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。